Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

[1]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[2]  D. Provencher,et al.  Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  K. Kelly,et al.  Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial , 2019, JAMA oncology.

[4]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[5]  G. Coukos,et al.  A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). , 2018, Annals of Oncology.

[6]  R. Boidot,et al.  Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy , 2018, British Journal of Cancer.

[7]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[8]  B. Vanderhyden,et al.  The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy , 2018, Cancers.

[9]  William H. Barry,et al.  Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer , 2018, Gynecologic Oncology.

[10]  Wyeth W. Wasserman,et al.  Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer , 2018, Cell.

[11]  L. Di,et al.  Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity , 2018, Clinical Cancer Research.

[12]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[13]  K. Kelly,et al.  Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials , 2018, Cancer.

[14]  A. Whittemore,et al.  Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer , 2017, JAMA oncology.

[15]  Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  B. Nelson,et al.  PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. , 2016, Gynecologic oncology.

[17]  R. Hollingsworth,et al.  Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models , 2015, Neoplasia.

[18]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[19]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[20]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[21]  C. Sessa,et al.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  C. Figdor,et al.  Ovarian cancer creates a suppressive microenvironment to escape immune elimination. , 2010, Gynecologic oncology.

[23]  D. Mutch,et al.  Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.